Trials / Completed
CompletedNCT01609049
An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis
Open-label, Multicenter, Non-Comparative, Prospective Observational Study to Evaluate Efficacy and Safety of Combined Ribavirin and Peginterferon Alfa-2a (40 kDa) Therapy in Patients With Chronic Hepatitis C (CHC) or Compensated Liver Cirrhosis in Real Clinical Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,496 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective observational study will evaluate the efficacy and safety of peginterferon alfa-2a in combination with ribavirin in participants with chronic hepatitis C, including participants with compensated liver cirrhosis, in clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Peginterferon alfa-2a | Administration of treatment will be according to local recommendation under local labeling. |
| DRUG | Ribavirin | Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice. |
Timeline
- Start date
- 2011-12-07
- Primary completion
- 2015-06-22
- Completion
- 2015-06-22
- First posted
- 2012-05-31
- Last updated
- 2017-04-12
Locations
57 sites across 2 countries: Russia, South Korea
Source: ClinicalTrials.gov record NCT01609049. Inclusion in this directory is not an endorsement.